Full-Time

Head of Marketing

Confirmed live in the last 24 hours

Vir Biotechnology

Vir Biotechnology

501-1,000 employees

Develops monoclonal antibodies for infectious diseases

AI & Machine Learning
Biotechnology
Healthcare

Compensation Overview

$235.5k - $329.5kAnnually

Expert

No H1B Sponsorship

San Francisco, CA, USA

Must be in-office 4 days per week.

Category
Brand & Creative Marketing
General Marketing
Growth & Marketing
Required Skills
Market Research

You match the following Vir Biotechnology's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • 12+ years of relevant in-line commercial experience at an early-stage biotech and/or pharmaceutical company, preferably in both large and small companies, developing and executing launch strategies
  • B.A./B.S. and MBA and/or advanced degree required
  • Substantial experience in product strategic planning, including developing differentiated brand positioning and messaging, as well as deep in-line experience, both pre-launch and post-launch
  • Working knowledge of current US payer environment and dynamics, including patient affordability programs
  • Strong analytical skills, demonstrated by the ability to identify and interpret complex issues and provide appropriate recommendations to senior management and across functional areas, including key market planning insights based on epi data and market research
  • Previous experience attracting, developing and retaining high caliber leaders and contributors that help build and shape the business to drive future success of the organization
  • Strong developmental leader who leverages this skillset to create a high performing organization
  • Ability to travel as required to meet business needs
  • Must plan to be in-office 4 days per week
Responsibilities
  • Lead the creation of the global brand plan and oversee the development and execution of the tactical plan in support of the overall brand strategy
  • Oversee pre-launch positioning and key message planning as well as post-launch tactical planning and implementation for Vir’s inline products
  • Maintain and modify our commercial launch readiness playbook; bring creative thinking in go-to-market approaches
  • Build integrated global strategic plans and budgets that meet market, regulatory, commercial and enterprise needs. Work with functional counterparts to achieve those plans and budgets
  • Be a key stakeholder in the refinement of forecasts, commercial budgets, and P&L for collaborations/products/programs
  • Develop and execute US launch campaigns, and global where applicable, including the development of a differentiating strategy, unique branding, compelling positioning and key messaging that maintain or extend our global market position
  • Shape, maintain and update the brand profile and develop key marketing deliverables, including value proposition, messaging, positioning, differential advantages, brand book and, in coordination with strategic partners to maximize revenue potential while ensuring strategic alignment and meeting patient needs
  • Conduct strategic marketing activities including market and competitive research and product positioning in close collaboration with cross commercial disciplines and partners as appropriate. Identify actionable insights based on market research and ensure that the product/brand addresses areas of unmet need. Ensure KPIs are relevant and informative for brand and patient objectives
  • Participate in portfolio prioritization and life cycle planning activities for relevant clinical-stage programs
Desired Qualifications
  • Any of the following experiences would be a plus: rare disease, building new markets/new therapeutic area commercialization and/or market development/activation experience

Vir Biotechnology develops treatments for infectious diseases by harnessing the immune system, using a proprietary platform for monoclonal antibodies (mAbs) combined with machine learning and artificial intelligence. Their pipeline includes clinical candidates for hepatitis B, hepatitis delta, and HIV, as well as monoclonal antibodies targeting influenza, COVID-19, and human papillomavirus. What distinguishes Vir from competitors is its collaboration with industry leaders and organizations to expedite scientific advancements. The company's goal is to transform lives by addressing unmet medical needs.

Company Size

501-1,000

Company Stage

IPO

Total Funding

$640.6M

Headquarters

San Francisco, California

Founded

2016

Simplify Jobs

Simplify's Take

What believers are saying

  • Increased interest in AI-driven drug discovery benefits Vir's AI capabilities.
  • The rise of personalized medicine aligns with Vir's monoclonal antibody focus.
  • Global pandemic preparedness funding supports Vir's broad-spectrum antiviral therapies.

What critics are saying

  • Leadership instability due to key executive resignations may disrupt operations.
  • Job cuts and facility closures indicate potential financial strain.
  • Struggles to diversify beyond COVID-19 antibody success may impact revenue growth.

What makes Vir Biotechnology unique

  • Vir Biotechnology uses AI-enhanced capabilities for monoclonal antibody development.
  • The company focuses on immune system manipulation for targeted therapies.
  • Vir's pipeline includes a potential functional cure for chronic hepatitis B.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Comprehensive healthcare coverage

Employer matched 401(k)

Employee stock purchase plan

Childcare assistance

Tuition reimbursement

Growth & Insights and Company News

Headcount

6 month growth

4%

1 year growth

2%

2 year growth

4%
U.S. Securities and Exchange Commission
Dec 5th, 2024
vir-10q_20200331.htm

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Investing.com
Aug 1st, 2024
Vir Biotechnology inks major deal with Sanofi unit

Moreover, Vir Biotechnology has entered into a significant licensing agreement with Amunix Pharmaceuticals, Inc., a Sanofi company.

MarketScreener
Aug 1st, 2024
Vir Biotechnology to Cut 140 Jobs in Restructuring to Focus on Hepatitis Drug Development

Vir Biotechnology to cut 140 jobs in restructuring to focus on hepatitis drug development.

Simply Wall St
May 5th, 2024
Earnings Update: Vir Biotechnology, Inc. (NASDAQ:VIR) Just Reported And Analysts Are Boosting Their Estimates

Vir Biotechnology, Inc. (NASDAQ:VIR) just released its quarterly report and things are looking bullish.

Investing.com
Apr 18th, 2024
Vir Biotechnology CFO Sung Lee to step down in May

Vir Biotechnology Inc. (NASDAQ:VIR) announced Monday that Executive Vice President and Chief Financial Officer Sung Lee will resign from his position effective May 3, 2024.